Spirovant Sciences

SP-102 Clin0 cystic fibrosis; 2 undisclosed programs RD respiratory conditions

Spirovant Sciences is developing novel gene therapies for the treatment of cystic fibrosis and other respiratory diseases. To date, several barriers have prevented effective gene therapies for cystic fibrosis. Using their adeno-associated virus platform that consists of an optimized transgene payload, a novel AAV capsid and au augmenter, Spirovant is creating highly effective gene delivery strategies for patients. The platform enables high expression of the functional cystic fibrosis transmembrane conductance regulator in human airway epithelia. With their AAV platform Spirovant has the unique opportunity to design tailored therapies for cystic fibrosis and other respiratory diseases with their lead program, SP-101 in preclinical stages.

Jobs: